Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Pursue a career where your passion lies. If that's in protecting the food we eat, stopping forest fires, keeping our parks and public lands pristine and accessible, planning wise land utilization, or ...